Chinese biotech company Bliss Biopharmaceutical (BlissBio) is reportedly considering a Hong Kong initial public offering (IPO ...

CATL’s 6.7 per cent discount to its Shenzhen-traded shares is much lower than the average 25 per cent discount for ...

Auntea Jenny is the latest of a string of tea companies to list in Hong Kong, just this year. Emily Tan takes a closer look at that market action.

Shares of the restaurant chain began trading at HK$7.19 per share, unchanged from the offer price, before plunging 7 per cent ...

AM, GIFT Nifty futures were trading 141 points higher at 25,220, suggesting a gap-up start for the Indian indices.

Hong Kong is calling for robotaxi operator Pony AI . The $6 billion Chinese company is exploring an offering in the city just ...

Alibaba reported a 93% YoY increase in operating income for the March 2025 quarter, driven by strong cloud revenue and sustained triple-digit growth in AI products. Total revenue rose 7% to RMB 236.5 ...

The underwriters on Hengrui Pharmaceutical Hong Kong listing are represented by Herbert Smith Freehills and Jingtian & ...

Jiangsu Hengrui Pharmaceuticals is planning to raise as much as US$1.27 billion via an initial public offering in Hong Kong, joining a wave of Chinese companies seeking to tap the city's market.

Singapore-based medical testing firm Mirxes joins Jiangsu Hengrui Pharmaceuticals in revitalised market's listing surge ...

China-based Jiangsu Hengrui Pharmaceuticals is seeking to raise up to HK$9.89 billion ($1.27 billion) in a Hong Kong initial public offering, according to a regulatory filing made on Thursday.